HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (5- chloro- 2- hydroxyphenyl)- 3- (2- chloro- 5- trifluoromethylphenyl)urea

an alpha7 nicotinic acetylcholine receptor modulator that may have cognitive enhancing activity; structure in first source

Also Known As:

NS 1738; NS-1738; NS1738

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - 1-(5-chloro-2-hydroxyphenyl)-3-(2-chloro-5-trifluoromethylphenyl)urea: 4
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        1-(5-chloro-2-hydroxyphenyl)-3-(2-chloro-5-trifluoromethylphenyl)urea: 4

Experts

1.	Damaj, M Imad: 2 articles (01/2018 - 01/2013)
2.	Freitas, Kelen: 2 articles (02/2013 - 01/2013)
3.	Jackson, Asti: 1 article (01/2018)
4.	Papke, Roger L: 1 article (01/2018)
5.	Björkholm, Carl: 1 article (01/2016)
6.	Feltmann, Kristin: 1 article (01/2016)
7.	Jardemark, Kent: 1 article (01/2016)
8.	Konradsson-Geuken, Åsa: 1 article (01/2016)
9.	Malmerfelt, Anna: 1 article (01/2016)
10.	Marcus, Monica M: 1 article (01/2016)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2016 - "In the present study we investigated, in rats, the effects of a selective α7 agonist (PNU282987) and a α7 positive allosteric modulator (PAM; NS1738) alone and in combination with the atypical antipsychotic drug risperidone for their utility as adjunct treatment in schizophrenia. "
2.	Pain (Aches) 02/01/2013 - "Our results indicate that the type II α7 nAChRs PAM PNU-120596, but not the type I α7 nAChRs PAM NS1738, shows significant anti-edematous and anti-allodynic effects in inflammatory and CCI pain models in mice." 01/01/2013 - "Our results indicate that type II α7 nAChR PAM PNU-120596, but not type I α7 nAChR PAM NS1738, shows significant antinociception effects in persistent pain models in mice." 02/01/2013 - "We tested two types of PAMS, type I (NS1738) and type II (PNU-120596) in carrageenan-induced inflammatory pain and chronic constriction injury (CCI) neuropathic pain models. " 01/01/2013 - "Testing type I [N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl] (NS1738)] and type II [1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl) (PNU-120596)] α7 nAChR PAMs in acute and persistent pain, we found that, although neither reduced acute thermal pain, only PNU-120596 dose-dependently attenuated paw-licking behavior in the formalin test. "
3.	Hyperalgesia 02/01/2013 - "We found that both NS1738 and PNU-120596 significantly reduced thermal hyperalgesia, while only PNU-120596 significantly reduced edema caused by a hind paw infusion of carrageenan. " 01/01/2018 - "The effect of the orthosteric α7 nAChR full agonist PNU282987 (1, 3, 9 mg/kg, s.c.), type I α7 PAM NS1738 (1 and 10 mg/kg; i.p.) and the type II α7 PAM PNU120596 (3 and 9 mg/kg, i.p.) on anxiety-like behavior, somatic signs, and hyperalgesia was measured in mice undergoing mecamylamine-precipitated nicotine withdrawal. "
4.	Neuralgia (Stump Neuralgia) 02/01/2013 - "We tested two types of PAMS, type I (NS1738) and type II (PNU-120596) in carrageenan-induced inflammatory pain and chronic constriction injury (CCI) neuropathic pain models. "
5.	Edema (Dropsy) 02/01/2013 - "We found that both NS1738 and PNU-120596 significantly reduced thermal hyperalgesia, while only PNU-120596 significantly reduced edema caused by a hind paw infusion of carrageenan. "

Related Drugs and Biologics

1.	PNU-282987
2.	Risperidone (Risperdal Consta)
3.	Antipsychotic Agents (Antipsychotics)
4.	1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)urea
5.	Nicotine
6.	Mecamylamine
7.	Formaldehyde (Formol)
8.	Carrageenan
9.	azastene